Caribou Biosciences

News

Adecto, Aviceda wind down, as Caribou seeks options

There may be a fairly buoyant operating environment for biotechs in the US, but Adecto and Aviceda are winding down, while Caribou is in peril.

Views & Analysis

Living the CRISPR dream

Caribou Biosciences, Inc., one of a handful of biotechs working on therapies based around gene editing, is at a pivotal point as it gears up for clinical trials of its CRISPR-based technology.

News

Iambic prices its IPO, seeking to raise up to $160m

AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks